Ongoing projects

  • CPI Government of Catalonia
  • RIS3CAT
  • ISCIII Ministry
  • International

The following projects have been co-financed by the European Union Regional Development Fund within the framework of the ERDF operational program of Catalonia 2014 - 2020:

The Feeding Care project aims to improve the system for the supply and storage of breast and artificial milk in the hospital environment. It is to optimize the prey or baby bottle according to the available stocks at the time of taking, the guidelines set by the medical or nursing professional, and the health status of the infant.

Feeding Care is a milk manager for hospitals that guarantees the traceability and the highest quality of products. It incorporates smart instruments through a mobile application that interacts with the intrahospital device.

The implementation of this project will improve the feeding safety of children under one year of age admitted to hospitals in Catalonia and reduce the costs incurred due to the loss of product.

    • Clinical Leader: Carmen Mendoza
    • Grant: 201.235,15 €

Colon and rectal surgery are increasing in developed countries. One of the common complications of this type of intervention is suture dehiscence, which is usually the result of poor vascularization of the anastomosis.

The Parc Taulí Health Corporation's project is based on the development of an objective and reliable system, which allows the surgeon to identify the areas most likely to suffer a suture dehiscence. This system integrates into the laparoscopy tower, relies on infrared light spectrometry captured through the laparoscope, and uses artificial intelligence.

Assessing intraoperative bowel vascularization will improve patient safety and reduce the costs associated with caring for this surgical complication.

    • Clinical Leader: Xavier Serra
    • Grant: 218.738,35 €

The public health system establishes different resources and circuits in order to respond to the demand for immediate citizenship care. This demand is embodied in situations that require a different care response: from situations that are life-threatening to the affected person and to demands for slight emergencies.

The Parc Taulí Health Corporation proposes a new digital symptom assessment (AS) system to prioritize patient care based on their level of urgency, as well as the implementation of an advanced resolution care unit. The model of care is based on a triage system using artificial intelligence, which categorizes patients into 5 levels of urgency.

The implementation of this project will reduce the waiting time for patients in hospital emergency services, facilitate the decision-making of healthcare professionals working in this area, save overall money, and improve the quality and safety of service.

    • Clinical Leader: Gilberto Alonso
    • Grant: 206.164,00 €

The aim of the project is to improve the quality, safety and variability of care for critical patients, through early and continuous care, which integrates the different clinical information and monitoring systems currently available in a support tool for the clinical decision making.

The term "extended ICU" refers to an innovative organizational system based on two elements: the collaboration of the entire medical and nursing team, both in the intensive care unit (ICU) and in other areas, in the identification and care of the critical patient during hospitalization; and the technological support for the early detection and follow-up of patients at risk of severe clinical deterioration before joining the ICU.

The project will implement: an early warning system that allows the detection and evaluation of a patient with a risk of serious worsening, codes of action in "time-dependent" diseases; and follow-up of critical patients before and after ICU admission.

Crítica-ContAs will contribute to the reduction of mortality, income and readmissions to the ICU, and the costs derived from them.

Collaborative project

    • Coordination: Catalan Health Institute
    • Parc Taulí Clinical Leader: Ana Ochagavia
    • Parc Taulí grant: 686.467,16 €

The initiative proposes a new model of care for the diagnosis and treatment of childhood type 1 diabetes to improve outcomes.

This model focuses on personalized medicine care, the application of optimally available technology, namely the continuous subcutaneous glucose diffusers (ISCI) or insulin pumps, and the introduction of a new monitoring platform that include 10 various control parameters (HbA1C glycosylated hemoglobin, severe hypoglycemia, diabetic ketoacids, and patient experience related parameters).

The implementation of the project will advance the actual concept of telemedicine or distance medicine, essential in a chronic illness such as type 1 diabetes, in order to replace on-site consultations, day hospital sessions, hospitalizations or emergency visits by a model based in virtual communication.

Collaborative project

    • Coordination: Sant Joan de Déu Hospital
    • Parc Taulí Clinical Leader: Jacobo Perez
    • Parc Taulí grant: 680.421,50 €

RIS3CAT Communities

The project "3DBONT ​​- 3D Biopsy for Tomosynthesis", aims to develop a prototype of a biopsy prono table to perform breast cancer scans with the tomography technique. This system will allow real-time biopsies to avoid sampling errors, higher photon capture efficiency, lower noise and high resolution, providing less diffused images, higher contrast and a lower radiation dose 50 times lower than conventional systems.

From CCSPT, work is being done to provide specifications for new image processing technology and the development of image reconstruction algorithms, which will allow validation after the first prototype has been manufactured.

  • Community Coordinator: LEITAT
  • Leading project entity: IDNEO / FICOSA
  • Principal Investigators CCSPT: Melcior Sentís and Josep Fernández
  • Subsidized cost accepted: 481.601,26 euros
  • FEDER grant (50%): 240.800,63 euros
  • Duration: July 7, 2016 - April 15, 2020
  • Consortium: IDNEO Technologies SL, Institute of Physics and Other Energies (IFAE), National Microelectronics Center (CNM), Baldomero Ventura SL, Parc Taulí Health Corporation Consortium (CCSPT)

The project "INNOBRAIN - New Technologies for Innovation in Cognitive Stimulation and Rehabilitation", aims to develop a neurocognitive rehabilitation platform based on multi-tactile interaction strategies to optimize human-computer interaction in cognitive rehabilitation. and to research in the field of ICT and e-Health technologies in the neurocognitive stimulation and rehabilitation of people with cognitive impairment or deficit.

The CCSPT is working on the application of ICTs in rehabilitation, monitoring the user at a behavioral and neurobiological level in real time by performing activities of daily living in a virtual way. In parallel, multi-touch interaction strategies, artificial intelligence technologies, and interactive videos are being clinically validated by monitoring rehabilitation in patients with DCA, schizophrenia, bipolar disorder, and dementia.

  • Community Coordinator: Biocat
  • Leading project entity: Guttmann Institute
  • Main CCSPT researchers: Diego Palao and Narcís Cardoner
  • Subsidized cost accepted: 110.301,10 euros
  • FEDER grant (50%): 55.150,55 euros
  • Duration: January 02, 2017 - December 31, 2019
  • Consortium: Guttmann Institute, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Girona Biomedical Research Institute (IdIBGi), UAB Health and Aging Foundation, Artificial Intelligence Research Institute (IIIA-CSIC), Computer Vision Center (CVC-UAB), Starlab Barcelona, ​​Sky & Earth. EURECAT, ICA, Parc Taulí Health Corporation Consortium.

The overall objective of the project "QuirofAM - Research in AM / I3D in the Health Industry for the Improvement of Surgical Practice" is the transformation of surgical practice by incorporating Additive Manufacturing (FA) at three levels: 'surgical trial, guides and implants for reconstruction and bioactive implants for tissue regeneration.

CCSPT brings the technological ability to make improvements at the core of design tools for digitally modeling living tissue, engaging in the research and development of new segmentation and conversion algorithms needed to be able to print anatomical patient structures from their CT and MRI scans. To have software that makes it viable to materialize data on highly complex living tissues in STL format.

  • Community Coordinator: LEITAT
  • Leading project entity: CIM Foundation
  • Principal Investigator CCSPT: Josep Fernández
  • Subsidized cost accepted: 297.923,46 euros
  • FEDER grant (24,16%): 71.968,42 euros
  • Duration: January 01, 2018 - December 31, 2020
  • Consortium: CIM Foundation, AVINENT, Institute of Bioengineering of Catalonia (IBEC), Sarrià Chemical Institute (IQS), TRACTIVUS, LEITAT, RICOH, VECMEDICAL, Sant Joan de Déu Foundation (FSJD), Sant Joan de Déu Hospital (HSJD), Parc Taulí Health Corporation Consortium (CCSPT)

PECT Sabadell

Specialization and Territorial Competitiveness project in Sabadell, Barberà del Vallès, Sant Quirze del Vallès and Castellar del Vallès

The object of this Specialization and Territorial Competitiveness Project (PECT) is the determination of a strategy and an operational plan agreed by the city councils of Sabadell, Barberà del Vallès, Sant Quirze del Vallès and Castellar del Vallès, the Design Foundation Textile (FUNDIT), the Eurecat Foundation, the Parc Taulí Foundation and the Autonomous University of Barcelona, ​​in order to achieve greater global economic competitiveness in the Vallès region, by specializing it in the field of system design and innovation. industrial.

The main objectives of this plan are:

  • positioning Vallès as a specialized driver of innovation and design in industrial systems;
  • the promotion of innovative and entrepreneurial culture and the support for the discovery of new technologies, new products and services;
  • commitment to the specialization of companies and occupational profiles through training and orienting their innovation towards meeting the needs of the territory.

A Vallès who bases his model of competitiveness and territorial development on continuing to lead the Catalan innovative industry, promoting it globally through an innovative ecosystem with collaborative participation of agents and specializing precisely in this cross-cutting function of design and innovation that all industries need to grow.

In recent years the desire to strengthen community bonds between people and to meet collective needs with social and / or environmental dimension has led to new ways of managing diverse social needs that involve processes of community empowerment and which promote alternative forms of consumption, of work, of production, and of relation.

Within the health sector, in line with the guidelines of the WHO and the EU, Catalonia has committed itself in the coming years to develop its own strategy to promote active and healthy aging, that is, to optimize, for all people without discrimination, their opportunities for physical, social and mental health, active participation in society and security, with the ultimate aim of enjoying a good quality of life and independence as they grow older.

The joint work between companies, Parc Taulí, social services and ESDI will mean creating synergies that promote technological transfer to the Vallès business and industrial park, in order to create new products aimed at improving the active aging and health of the population. seniors.

Objectives of the operation:

  • Revitalization in the territory of a meeting place between companies, design professionals and the user of the product or service, in order to innovate in the design and manufacture of equipment and in the development of services for healthy and active aging. . -GREAT PEOPLE-
  • Development of a system for identifying the needs, motivations and interests of the different agents involved.
  • Strengthening synergies for the creation and evaluation of proposals for new products and services for healthy and active aging.
  • Pilot tests of any of the ideas developed.

The following projects have been co-financed by: ERDF - European Regional Development Fund:

2019

Prader-Willi Syndrome (SPW) is a genetic disease associated with growth hormone deficiency (GH), central hypotonia, and hyperphagia with a risk of severe obesity. GH treatment in the adult patient is not well established in the NHS guidelines. Our group has experience in studying brain connectivity in this type of patient in relation to satiety. So far there is no evidence of the effect of GH on central hypotonia (brain areas involved in maintaining muscle tone).

El main goal is to study these areas before and the year of GH treatment.

Methodology: Structural and functional magnetic resonance imaging in 30 patients with adult SPW before and after GH, compared with a control group.

Expected results: The SPW group will show altered functional and structural connectivity in the areas that control muscle tone and will improve after GH treatment. These favorable changes and the absence of serious side effects will help justify the use of this treatment and its inclusion in the SNS clinical practice guidelines for the management of this syndrome in adulthood.

    • IP: Dr. Assume Pedragos Boxes
    • Endowment until the third annuity: 177.870,00 €

2018

Prader-Willi Syndrome (SPW) is a genetic disease associated with growth hormone deficiency (GH), central hypotonia, and hyperphagia with a risk of severe obesity. GH treatment in the adult patient is not well established in the NHS guidelines. Our group has experience in studying brain connectivity in this type of patient in relation to satiety. So far there is no evidence of the effect of GH on central hypotonia (brain areas involved in maintaining muscle tone).

El main goal is to study these areas before and the year of GH treatment.

Methodology: Structural and functional magnetic resonance imaging in 30 patients with adult SPW before and after GH, compared with a control group.

Expected results: The SPW group will show altered functional and structural connectivity in the areas that control muscle tone and will improve after GH treatment. These favorable changes and the absence of serious side effects will help justify the use of this treatment and its inclusion in the SNS clinical practice guidelines for the management of this syndrome in adulthood.

    • IP: Dr. Assume Pedragos Boxes
    • Endowment until the third annuity: 177.870,00 €

The glucose sensors, key elements in the current management of diabetes, being inserted for days in the subcutaneous tissue, provoke an inflammatory reaction that conditions its effective duration and the quality of the measurement. Initial studies in animal models aimed at the leading role of macrophages, cells that consume oxygen and glucose, in the functional commitment of the sensors. We have recently shown, for the first time in humans, that the magnitude of the macrophage cluster around the sensor over the past 7 days is related to glucose measurement error.

The purpose of the study we propose is twofold: on the one hand, to reproduce the methodology used in similar sensors with a longer duration (14 days), and on the other, to characterize the inflammatory response and its impact on reliability in 180-day implantable sensors. that incorporate dexamethasone to inhibit this response and in which a clear interindividual variability in the functional survival of the sensor is also described.

    • IP: Dr. Mercedes Rigla Cros
    • Endowment until the third annuity: 62.920,00 €

The lack of biomarkers for the diagnosis and treatment of depressive disorders is a critical limitation for their clinical approach. Analysis of fast-acting antidepressants has been proposed as a promising strategy for identifying new valid biomarkers. In this context, our group proposes electro-convulsive therapy (ECT), the fastest and most effective clinical treatment for treatment-resistant depression (DRT), as a model for the study of biomarkers.

The present study uses a translational approach, based on brain changes and protein expression analysis, in 1) a cohort of DRT patients treated with ECT, 2) a cohort of DRT patients treated with conventional antidepressants, and 3) in a model of depression in rats treated with electroshock (ES). Blood proteins will be analyzed and neuroimaging data collected.

Differences in neuroimaging and proteomic data were compared with a healthy control group, and between baseline and post-treatment in patients treated with ECT. The results will be included in a parallel independent component analysis (PICA) to identify proteins that are associated with brain changes. Subsequently, the expression of these proteins in the blood and brain tissue of ES-treated rats was analyzed.

Finally, these changes will be evaluated in an independent cohort of DRT patients treated with antidepressant drugs, to analyze the possible generalization of these biomarkers in other treatment strategies.

    • IP: Dr. Narcis Cardoner Alvarez
    • Endowment until the third annuity: 208.120,00 €

OBJECTIVES: To carry out a project with an epidemiological, clinical and experimental approach to the study of the factors associated with psychotic experiences in adolescent population with a special emphasis on cognitive biases. Assess whether clinical and biological stress-related factors are associated with psychotic experiences or high-risk mental state criteria (EMAR). Exploring through a pilot clinical trial whether a group psychotherapeutic intervention on social skills and meta-cognition may be implementable to reduce cognitive bias and psychotic experiences in adolescents.

METHODS

  • Phase 1. Epidemiological study. Sample of adolescents (cohort born in 2004; 15-16 years old; 2490 students in Sabadell). On-line questionnaires to determine psychotic experiences (CAPE), cognitive bias (CBQ) and cannabis use and other toxic substances.
  • Phase 2. Selected clinical study on previous sample. N = 270 (180 adolescents with psychotic experiences + 90 adolescents without these experiences). Evaluation of adolescents with psychotic experiences with CAARMS to diagnose EMAR. Comparison of 3 groups (non-experiences vs non-EMAR psychotic experiences vs. EMAR) in a series of clinical variables (neurocognitive skills and social cognition with the CANTAB; history of childhood maltreatment (CTQ); stressful events; stress biomarkers [cortisol, prolactin, serum inflammatory factors; cortisol in saliva and hair]).
  • Phase 3. Pilot clinical trial. Selection of 40 participants from the EMAR group to carry out a randomized intervention on social skills and meta-cognitive training (MOSST). Subsequent evaluation of clinical parameters (psychotic experiences, cognitive bias, neurocognition and social cognition, perceived stress, biomarkers of stress).
    • IP: Dr. Javier Labad Arias
    • Endowment until the third annuity: 87.120, 00 €

Acute respiratory distress syndrome (ARDS) is the result of acute respiratory failure which is associated with high morbidity and mortality without specific treatment. The lungs of patients with DSDD are characterized by an acute inflammatory response and a coagulation activation. Recent evidence shows the beneficial effects of cell therapies and anticoagulant nebulization on acute lung injury (LPA) due to their action on various pathophysiological pathologies. The combination of both treatments could be an improvement for the treatment of SDRA.

El main goal of this novel project is to determine the therapeutic potential of a combination cell therapy with antithrombin III (ATIII) in LPA. We analyzed the effect of mesenchymal stem cells, type II alveolar cells or their conditioned media together with the administration of ATIII, in vitro and in vivo on HCl / Lipopolysaccharide-induced LPA. The action in different pathophysiological pathways of SDRA enhances its beneficial effect by modulating the inflammatory and pro-coagulant response and improving tissue repair.

    • IP: Dr. Antonio Artigas Raventós
    • Endowment until the third annuity: 111.320,00 €

Multicenter mixed-method study from three sub-studies of which goals They are:

  1. To know the experience, satisfaction and participation in decision-making of the participants in the colo-rectal cancer screening program (CCR) with a positive result in the stool of occult blood (TSOH) with respect to the screening process.
  2. To evaluate the experience, satisfaction and participation in decision-making during the diagnostic and therapeutic process of patients diagnosed with CCR through the program.

Methodology:

  • Sub-study1- Development of a questionnaire to measure the experience and satisfaction of participants with a positive TSOH regarding the screening process: scope review, development of the questionnaire and pilot test with a sample of participants.
  • Sub-study 2: A multicenter cross-sectional study (3 hospitals) to know the participation in decision-making, the experience and satisfaction of participants with a positive TSOH in relation to the screening process and the diagnostic-therapeutic process of cancer. 850 participants with a positive TSOH will be included, classified according to their final diagnosis (false positives of TSOH; polyps; CCR) and the results will be compared between groups. The variables of interest will be measured by self-administered questionnaires: RATE, SDM-Q-9, OUT-PATSAT35 and the questionnaire developed in the sub-study1.
  • Sub-study3: qualitative study to gain in-depth knowledge of the perception and experience experienced by participants with a positive TSOH. We will use a phenomenological methodology, conduct discussion groups and individual interviews and make a thematic analysis of the content. The results of this project will identify areas for improvement in order to get really focused attention on people.
    • IP: Dr. Anna Selva Olid
    • Endowment until the third annuity: 45.980,00 €

OBJECTIVES: To study the impact of viral respiratory infection in cystic fibrosis (CF) on the respiratory and intestinal bacterial microbiome:

  1. Analyze the microbiome composition in the stable CF.
  2. To determine the changes in the microbiome associated with respiratory viral infection, and the pathogenicity linked to these changes.
  3. To determine the temporal persistence of microbiome modifications following viral infection.
  4. Identify changes in the respiratory inflammatory pattern associated with viral infection, and their relation to the composition of the microbiome.
  5. To determine the correlation between the microbiome and the evolution of the disease after a viral infection.
  6. Identify the information provided by the analysis of the respiratory virus, in stability and exacerbation by viral infection, in addition to conventional virology.

SECONDARY OBJECTIVES: Compare bacterial microbiome of supra-gluteal airway (nasal lavage, aspiration of pharyngeal gold) and infra-glottis (sputum) in stable condition and during exacerbation by viral infection.

METHODS: A cohort of CF patients will be set up at pediatric and adult clinics. Samples of nasal aspirate (N), pharyngeal gold aspirate (OP), sputum (E) and stools (H) will be collected monthly (September-April). The same set of samples will be collected at the time of viral exacerbation and in the 3 weeks following. The microbiome will be determined by conventional microbiology and 16S rRNA amplification and sequencing. The functional genomic target and resistoma will be determined by shotgun sequencing. Respiratory viruses will be identified by nested-PCR and microarray reading and Shotgun sequencing virus studies, and immune response markers (IL1b, IL8, IL12, IL17, EN) (LUMINEX, ELISA) will be determined. Finally, all data will be integrated through system biology.

    • IP: Dr. Eduard Monso Molas
    • Endowment until the third annuity: 208.120,00 €

The overall aim of the study is to test the validity of neurovascular stroke and thoracoabdominal synchronization as pathophysiological markers of dyspnea, and to determine the degree of their correlation with FEV1 and their importance as descriptors of the severity of chronic obstructive pulmonary disease (COPD). . Specifically, to establish neuroventilatory decoupling, non-invasive sensors such as the electromyogram for sternum will be used to determine the start of electrical activation of the respiratory muscles, along with a pneumothorax that will determine the mechanical onset of inspiration.

We will also measure the degree of thoracabdominal asynchrony as a surrogate to the degree of airway resistance through inductance plethysmography and automated signal processing by calculating the phase angle on the two-dimensional graph of thoracic displacement versus abdominal displacement (Lissajous figures). ). Said parameters (neuroventilatory coupling and thoracoabdominal synchrony) will be studied in a basal situation, during effort on a cycloergometer and under non-invasive ventilation. They will be correlated with the clinical (functional Borg scale dyspnea) and functional (forced spirometry) parameters in clinical practice.

    • IP: Dr. Manuel Luján I returned
    • Endowment until the third annuity: 18.150,00 €

Over the last few years, knowledge about Bartonella has grown significantly. Until the XNUMX's, very few species had been described. However, due to improvements in molecular and culture techniques, the number of species described in recent years has grown considerably. Also, greater variability in clinical manifestations and greater complexity in their epidemiology have been described, with information yet to be elucidated regarding the role of some reservoirs and possible vectors such as ticks. On the other hand, from the point of view of microbiological diagnosis, the techniques of culture and molecular biology have improved substantially, so we have very powerful tools for the clinical and epidemiological study of these infections.

The aim of this project is to study the presence of Bartonella in vectors, pets (dogs and cats) and humans (patients with a clinic or people with risk factors for infection) and the epidemiological relationship between them, as well as confirm their increase. incidence and clinical spectrum.

Human, pet and vector samples will be studied. Different techniques will be applied to detect the presence of Bartonella (Tick-Borne Bacteria Flow Chip, immunohistochemistry and enriched culture) and the species detected will be identified by sequencing. The clinical and epidemiological characteristics of the confirmed cases will be described.

    • IP: Dr. M. Esperanza Anton Nieto
    • Endowment until the third annuity: 77.440,00 €

2017

Accurately describe the incidence of different types of patient-ventilator asynchronies and poor interactions in hypoxemic patients with VM, including those with SDRA, and evaluate their association with prognosis (duration of VM, mortality). Mutivariate analyzes that take prognosis as the dependent variable and each asynchronous type as an independent variable will explore the strength of associations after adjustment for multiple confounding factors.

    • IP: Dr. Lluís Blanch Torra
    • Endowment until the third annuity: 217.554,27 €
    • Case file: RTC-2017-6193-1

These more than 10 years working on the consolidation of the innovation model implemented in the Parc Taulí Institute has led us to present new objectives focused on the acceleration of projects, transfers and their arrival to the market and the extension of the scope of the model including the working methodologies needed to respond to process innovation and the adoption of innovative public procurement processes by hospital structures in favor of the purchase of new technologies that provide greater efficiency.

These are our main challenges as a result of the institutional commitment to innovation that is present in many aspects and which are defined in the current strategic plan (2015-2019 period). This strategic plan contemplates three great strategic axes:

  1. Growth through the integration of researchers and groups of the entities that make up the Institute, internationalization, the promotion of network research, the promotion of clinical research and the recruitment of talent.
  2. Provide the Institute with the organizational model of the Institutes of Health Research as a means to maximize efficiency, gradually implementing the different plans and indicators required and adapting the structures and activity registers.
  3. Adaptation of the management structures to the impulse needs of the INNOVATION as a differentiating element in the framework of a strategy of specialization and of generating social and economic impact in the territory.

In this last axis we will focus on building our proposal of work in ITEMAS for the next period in line with the strategy of the Institute, and which will be developed with the following concrete objectives:

  1. To stimulate, develop and implement innovation in processes
  2. Acceleration of the arrival of products to the market and their transfer to the clinic, enhancing their transfer to the care and productive tissue, maximizing the impact on the territory.
  3. Encourage the generation of new innovation opportunities (communication plan, dissemination of results, ...)
  4. Increase the number of projects transferred to the market and / or implemented in the health system.
  5. Active participation in the work groups defined by the Itemas platform.
    • IP: Dr. Lluís Blanch Torra
    • Endowment until the third annuity: 213.510,00 €

Objective: To evaluate the impact of the detection and treatment of bacterial vaginosis in the first trimester of gestation, on the preterm birth rate of the general population of pregnant women.

Method: Phase IV randomized, double-blind, multicenter national clinical trial.

Subjects: Gestants of the general population asymptomatic carriers of bacterial vaginosis (Nugent criteria ≥ 4) in the first trimester of gestation.

Inclusion criteria: Unique gestations <15 weeks, without symptoms suggestive of bacterial vaginosis.

Exclusion criteria: Multiple gestation, symptoms suggestive of bacterial vaginosis, fetal or maternal pathology present in the first trimester, which may interrupt the gestation.

Intervention: Patients with asymptomatic carrier of bacterial vaginosis (Nugent criteria ≥ 4), will be randomly assigned to one of the two branches of the study to:

  • Study group: oral clindamycin 300 mg / 12h 5 days
  • Placebo group: placebo capsules with identical characteristics and dosage. The randomization will be centralized online and managed by the CTU of the Hospital Clínic de Barcelona.

Main result: Pregnant preterm <34 and <37 weeks.

Secondary results: Early gestation <32 and <28 weeks and second trimester losses (≥ 15- <24 weeks).

The execution period of this project began on January 1, 2018 and will end on December 31, 2020, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI17 / 01712 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII) - General Evaluation Sub-directorate and the European Regional Development Fund (ERDF).

    • IP: Dr. Agueda Rodriguez Vicente
    • Endowment until the third annuity: 5.626,50 €

BACKGROUND: Suicide is the leading cause of violent deaths. In 2014, the Dept. Salud de Catalunya implemented the Suicide Risk Code (CRS), an intervention program in cases of high risk of suicide, with full geographical coverage since 2016. OBJECTIVES : A) estimating the population incidence of the attempt and the repetition of the suicide attempt; B) identify the clinical, demographic, psychometric, neuropsychological and biological factors and the stress response (psychoneuroendocrine, inflammation, genetic and neuroimaging markers) in suicide attempts; and C) evaluate the effectiveness and cost of the Suicide Risk Code (CRS) program.

METHODOLOGY: SUBPROJECT 1: A longitudinal study of the dynamic cohort of individuals registered in the CRS (expected n = 10.000). The variables come from the CRS register and from the link with the health and mortality records (PADRIS program). Will estimate: population incidence of suicide attempt; the incidence of repeated suicide attempts in the CRS; baseline risk factors for repeated suicide attempts; and effectiveness (deaths avoided); and the costs of the CRS program. SUBPROYECT 2 is a study of clinical sub-cohorts of a sample of hospital patients in the CRS program (n = 900), evaluated clinically (neuropsychological variables, psychoneuroendocrine, inflammatory, genetic and neuroimaging markers), followed by 18 months and compared with control groups (repeaters vs. non-repeaters and healthy).

The execution period of this project began on January 1, 2018 and will end on December 31, 2020, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI17 / 01205 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII) - General Evaluation Sub-directorate and the European Regional Development Fund (ERDF).

    • IP: Dr. Diego J. Palao Vidal
    • Endowment until the third annuity: 106.480,00 €

Cross-sectional studies have described in migrants rates of colonization by multidrug-resistant bacteria (BMR) higher than those observed in the native population.

Objectives:

  1. To evaluate the prevalence of intestinal colonization by broad-spectrum beta-lactamase-producing enterobacteria (EBLEE), carbapenemase (EPC) and vancomycin-resistant enterococcus (EVR) in people from non-European countries.
  2. To study the genetic lineage of isolated BMRs and the enzymes involved in their antibiotic resistance.
  3. To analyze the risk factors for BMR colonization.
  4. To study the associations between BMR colonization and the composition and diversity of the gut microbiome.
  5. To study the factors related to the persistence in the colonization after the arrival to our country.

Methodology: A multicenter cross-sectional study involving four primary care centers and two tropical disease services. Inclusion of migrant subjects during the first quarter after their arrival in Spain. Epidemiological data collection. Rectal smear screening for BMR detection. Incubation and seeding in selective chromogenic media. Identification by MALDITOF MS (MALDI-Biotyper®) and microdilution antibiotic sensitivity (MicroScan®). PCR will study the resistance genes of the EBLEE, EPC and EVR isolates. Genotyping by pulsed field electrophoresis and representative selection of isolates will also be studied by MLST. Bacterial microbiome analysis will be performed by amplification and sequencing of the 16S rRNA gene. At 6 months, new epidemiological data collection and screening of the subjects with some positive sample for BMR in the first screening. Analysis of risk factors for colonization and persistence of colonization using logistic regression models.

The execution period of this project began on January 1, 2018 and will end on December 31, 2020, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI17 / 02102 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII) - General Evaluation Sub-directorate and the European Regional Development Fund (ERDF).

    • IP: Dr. Oriol Gasch Blasi
    • Endowment until the third annuity: 64.130,00 €

Introduction: Helicobacter pylori is the main causative agent of gastric diseases and the main risk factor for the development of gastric adenocarcinoma. In vitro studies with this pathogen use tumor cell lines as a model of infection. However, these cell lines do not have a normal cell physiology, nor are they representative of the integral gastric epithelium. A solid, almost immortal human gastric organoid (OGH) model has recently been established. Based on the histology and expression of markers, this model retains many of the characteristics of its respective tissue of origin. OGH is a valuable tool in studying the epithelial response to H. pylori infection. We will use this method to generate organoids at the different stages of the infection that lead to gastric cancer.

Objectives: To investigate, using organoids, the morphological profile and gene expression 1) of organoids obtained from biopsies of patients without infection of the body and body and subsequently infected with H. pylori 2) obtained from patients with chronic gastritis, preneoplastic gastric lesions (atrophy). , metaplasia) and gastric cancer. These results can be used to predict the carcinogenic potential of H. pylori and to predict the Correa cascade (chronic gastritis, preneoplastic lesions, and gastric cancer).

Methods: We will generate organoids from human gastric and body gastric biopsies from dyspeptic patients without H.pylori and infect them with virulent and non-virulent strains of the bacterium. In addition we will generate organoids from patients with: i) infection ii) metaplasia iii) gastric cancer. We will evaluate the response to the infection based on morphological changes, cytokines and gene expression (mRNA / miRNA). The results will be correlated with the clinical, microbiological and histopathological findings.

The execution period of this project began on January 1, 2018 and will end on December 31, 2020, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI17 / 01564 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII) - General Evaluation Sub-directorate and the European Regional Development Fund (ERDF).

    • IP: Dr. Xavier Calvet Calvo
    • Endowment until the third annuity: 92.202,00 €

The psychological, cognitive and physical aftermath of critical illness can be compounded by the high levels of stress that patients experience in the Intensive Care Units (ICUs). At present it is necessary to reconsider the re-humanization of care with initiatives that improve the relationship between patients, family and healthcare professionals, always considering the benefit of the patient, but without increasing the burden of care or the human and economic costs.

El overall objective of this project is to develop and implement a multifunction system with 4.0 technological tools that facilitate humanized care in the ICUs. The users of the system will be both patients, family and clinical professionals, which will complement the evolution, accompaniment and medical treatment with aspects of humanization. Virtual Reality techniques for the application of physical and cognitive rehabilitation during the ICU stay will be included and Internet of Things (IoT) solutions will be implemented, ensuring the interconnectivity of the devices in the ICU ecosystem. Finally, the system will include an integration engine that allows the capture, storage and analysis of massive data that can be integrated into the medical history, with the aim of generating predictive models for the continuous improvement of care.

This aid is co-financed by the European Regional Development Fund, Intelligent Growth Operational Program 2014-2020 (Thematic objective "Enhancing research, technological development and innovation"; Specific Objective "Fostering and generation of border knowledge and knowledge oriented to the challenges of society, the development of emerging technologies "; Action" Research projects aimed at the Challenge of Health, Demographic Change and Welfare ".

The execution period of this project began on January 1, 2018 and will end on December 31, 2019.

    • IP: Dr. Lluís Blanch Torra
    • Endowment until the third annuity: 70.400,00 €

2016

REDISSEC is built on three main issues: the challenge of managing the phenomenon of chronicity, the need to have more and better information and the obligation to increase research capacity in health care policies and services in Spain.

Chronic diseases (EC) are by far the leading cause of death in Europe and Spain, accounting for more than two-thirds of all deaths. The economic implications of such a burden of disease are also notable.

Despite recent advances, most health care for EC is still structured around acute exacerbations of the disease. For this reason, the management of chronic diseases is increasingly considered a major concern for policymakers and researchers. Probably the elements that best shape the current healthcare environment are: the concern of governments and societies about the growing spending on health; the existence of large variations in medical practice that are not explained by differences in the morbidity of populations; Concerns about the efficacy, safety and efficiency of new technologies and medicines, and the quality of medical practice and healthcare organizations; the revolution in information and communication technologies, along with the promise of their impact on the health sector; and the increasing involvement of patients in clinical decisions. Health Services research in Spain has grown over the last 20 years, mainly around small research groups. Although some previous efforts may be worth noting, it was not until 2004 that research in health services appeared as a priority area of ​​research in the National Research Plan 2004-2007.

REDISSEC's ability is based on previous Collaborative Research experience in most participating groups. This collaborative strategy has led to the creation of an initiative composed of 14 research groups from 9 Autonomous Communities. REDISSEC is aware of its potential in terms of capacity building for health services research in chronic diseases; however, REDISSEC is also aware of the many research questions and knowledge gaps that will require additional strategies from networking, at national and international levels.

This work is funded by the RD16 / 0001/0002 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF)

The execution period of this project began on January 1, 2017 and will end on December 31, 2021, following a ISCIII evaluation carried out at the end of the third year.

    • IP: Dr. Mª Lluïsa Baré Mañas
    • Financial endowment: 109.829,50 €

The purpose of the RIS is to guarantee a high level of quality of HIV / AIDS research and to encourage the continuous improvement of the results in the National Health System, through the cooperation of quality groups from different institutions.

Objective:

  • The relevance of these in the current scenario of AIDS research
  • The previous experience of the participating groups, their level of excellence and their international competitiveness.
  • The ability to combine strategies and competencies to perform a global approach to these questions that would be unrealizable outside of networking

This work is funded by the RD16 / 0025/0033 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF)

The execution period of this project began on January 1, 2017 and will end on December 31, 2021, following a ISCIII evaluation carried out at the end of the third year.

    • IP: Dr. Gemma Navarro Rubio
    • Financial endowment: 38.500,00 €

The Spanish Network for Research in Infectious Pathology (REIPI) is an inter-territorial research space within the Thematic Networks of Cooperative Health Research (RETICS), through the "Carlos III Health Institute", Ministry of Science and Innovation, Twenty-five research groups from seven autonomous communities, from the Health System, the University and the Higher Council for Scientific Research, take part.

The groups that constitute it have the objective of producing scientific knowledge in the field of infectious diseases, grouping microbiologists, infectologists and immunologists, linked to basic, translational and clinical-epidemiological research groups.

The areas of work of the REIPI are diverse, including their research groups, especially those from the Health System, to a significant number of researchers. Thus, REIPI focuses on antimicrobial and microbial resistance, community and hospital infections, infections in immunosuppressed patients, and the molecular basis of pathogenesis, diagnosis and treatment of infections. On the other hand, since the knowledge produced is intended to ultimately transfer patients, the main strategic objectives are grouped into thirteen Health Problems, defined by the Scientific Committee of the Network.

This work is funded by the RD16 / 0001/0002 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF)

The execution period of this project began on January 1, 2017 and will end on December 31, 2021, following a ISCIII evaluation carried out at the end of the third year.

    • IP: Dr. Oriol Gasch Blasi
    • Financial endowment: 8.519,00 €

Given the difficulty involved in handling and interpreting the large amount of data that is handled in the ICUs, the target of the project is to provide service staff with technological developments that facilitate care work specifically focused on improving patient-ventilator interaction to reduce the incidence of asynchronies and to optimize the timing of the removal of mechanical ventilation. In mechanical ventilation (VM) the use of an expert system can bring great benefits. Patient-ventilator asynchronies are associated with worse prognosis and may be responsible for underlying clinical changes, including prolonged VM time increase the risk of complications. Extubation failure has been significantly associated with an increased incidence of ventilator-associated pneumonia and high mortality. The development of Smart Data Display tools can facilitate knowledge and decision-making and positively reduce the risk of complications.

Methodology: The study will be developed in the ICU of the Parc Taulí University Hospital. We will generate a large database collected continuously in patients admitted to the ICU who require mechanical ventilation. We will design algorithms that facilitate the interpretation of them. On the basis of this we will implement a simple tool (Smart Data Display) in the form of a screen that facilitates the daily practice for the support staff and analyze the results after this intervention.

This work is funded by the PI16 / 01606 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF)

The execution period of this project began on January 1, 2017 and will end on December 31, 2019.

    • IP: Dr. Lluís Blanch i Torra
    • Financial endowment: 80.465,00 €

About 10% of patients with SA phenotype remain without genetic diagnosis. It is believed that genes responsible for the SA phenotype are yet to be identified. The function of the UBE3A gene, responsible for SA, is complex and a deficit at some point in its molecular network may contribute to the characteristics associated with SA. In fact, many syndromes that exhibit a phenotype that overlaps with SA are caused by mutations in genes whose function interacts with UBE3A.

We propose the use of exome sequencing in 16 parent-patient trios to identify new candidate genes responsible for the SA phenotype. Simultaneously, we will characterize the underlying molecular interactions in order to increase understanding of the biological functions associated with the UBE3A gene and SA phenotypes. Identification of new candidate genes and pathways involved in the phenotype may lead to the design of new targeted therapies.

In addition, a better description of the clinical and neurocognitive phenotype associated with the identified molecular alterations will be made, which may lead to a different therapeutic approach and therefore to a better quality of life for patients with SA and their families.

Finally, a new genetic diagnostic algorithm will be developed that includes a panel of gene sequences, including the UBE3A gene, other known genes that cause an SA phenotype and the new candidate genes, to increase the success rate of molecular diagnosis in those patients displaying a SA phenotype. Early molecular diagnosis is crucial for optimum clinical management and genetic counseling.

This work is funded by the PI16 / 01411 project integrated into the National R&D Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF).

The execution period of this project began on January 1, 2017 and will end on December 31, 2019.

    • IP: Dr. Miriam Guitart Feliubadalo
    • Financial endowment: 62.315,00 €

Gestational diabetes is the most common metabolic disorder in pregnancy, affecting at least 9% of all pregnancies. Without treatment, hyperglycemia causes complications such as macrosomy, which increases the risk of birth injuries and metabolic disorders in the first hours of life. The key parameters for monitoring are fasting blood glucose and postprandial glycemia. Glucose levels tend to increase progressively throughout pregnancy, and if they become inadequate despite a quantitative diet and exercise, insulin treatment will be required. To ensure that the glycemic values ​​are correct, the care protocols recommend that visits be made weekly or at most bi-weekly, which is an enormous workload.

We have developed and tested in a randomized clinical trial an intelligent web application that classifies blood glucose data and generates automatic messages to the patient with diet change proposals to correct hyperglycemia and / or ketonuria and alerts the patient and the care team if considered the need to initiate insulin treatment is likely. The clinical study has shown the safety, efficacy and high satisfaction of the patients. The target of this project is to adapt the application for use on mobile (android), integrate a measure of physical activity and adapt and customize the recommendations according to the prescribed level of activity.

This aid is co-financed by the European Regional Development Fund, Intelligent Growth Operational Program 2014-2020 (Thematic objective "Enhancing research, technological development and innovation"; Specific Objective "Fostering and generation of border knowledge and knowledge oriented to the challenges of society, the development of emerging technologies "; Action" Research projects aimed at the Challenge of Health, Demographic Change and Welfare ".

The execution period of this project began on January 1, 2017 and will end on December 31, 2018.

    • IP: Dr. Mercedes Rigla Cros
    • Financial endowment: 33.000,00 €

2015

Sepsis is a frequent and severe clinical entity that is defined as a potentially life-threatening severe infection with a life-threatening cytosine-mediated hyperinflammatory response to multiorgan dysfunction (MOF). It is the most common cause of death in most intensive care units. The pathophysiology of sepsis is not fully known, although the analysis of biomarkers in patients with sepsis has provided us with relevant information about this process. In-depth study of the cellular response and molecular mechanisms that occur in the presence of these biological mediators and which are involved in the development of MOF, seems a priority for

propose new effective therapeutic strategies. Currently, no drug treatment has been beneficial for the treatment of sepsis, which is why new therapeutic alternatives are being proposed. Mesenchymal stem cells (MSCs) have anti-inflammatory, antimicrobial, antiapoptotic, and cell permeability-regulating properties, and it is logical to think they could be a good therapy for sepsis, as they would act at different levels and in a systemic way. Our group raises the possibility of improving its specific therapeutic potential depending on the pathophysiological changes observed. Genetically modified MSCs will be administered as

treatment in our animal model of sepsis and the main hypothesis of this project is that treatment with these cells will reduce damage and control the inflammatory response, improving microcirculation, reducing MOF and decreasing mortality.

The execution period of this project began on January 1, 2016 and will end on December 31, 2018, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI15 / 02204 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF).

    • IP: Dr. Antoni Artigas Raventós
    • Financial endowment: 86.515,00 €

Objectives:

  1. Estimate and describe patterns of multimorbidity and polymedication in patients over 64 years of age who suffer from exacerbated chronic pathology.
  2. Analyze potentially inappropriate prescription (PPI) of drugs according to STOPP / START (SS) criteria.
  3. To evaluate the relationship between multimorbidity and PPI and preventable adverse drug reaction (RAM).

Methods: A prospective multicenter randomized sample of 1200 admissions in the internal medicine and / or geriatric services of 5 general SNS hospitals. Terminal patients with a life expectancy of less than 1 year will be excluded. Application of the SS criteria at admission and discharge, and collection of sociodemographic, clinical variables including comorbidities and geriatric syndromes, chronic basal medication, functional capacity, and RAM. A descriptive and bivariate analysis will be performed using parametric or non-parametric tests according to variables, including morbidity, polymedication, SS criteria and RAM. Multiple regression techniques will be applied, where the dependent variable will be the PPI or the RAM.

The execution period of this project began on January 1, 2016 and will end on December 31, 2018, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI15 / 00552 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF).

    • IP: Dr. Maria Lluïsa Baré Mañas
    • Financial endowment: 58.080,00 €

Patients with bipolar disorder have neurocognitive deficits, which are apparent not only during affective episodes but also during the symptoms remission phases and are associated with significant functional repercussions. However, the number of studies on neurocognitive rehabilitation in bipolar disorder is very small. This entails the need to research new effective, more creative and innovative interventions to reduce cognitive deficits in order to reduce costs and increase patient benefits.

This project has like target check the efficacy of the Neuropersonaltrainer a computerized neurocognitive module as an adjunct to functional rehabilitation intervention. Patients completing the initial functional rehabilitation intervention will be randomized to an extension of the study consisting of 12 weeks of training with the e-neurocognitive module, in order to test the effectiveness of this new intervention on psychosocial functioning in bipolar disorder. Clinical, neuropsychological and neuroimaging variables will also be evaluated as secondary outcome variables.

The execution period of this project began on January 1, 2016 and will end on December 31, 2018, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI15 / 01478 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF).

    • IP: Dr. Narcissus Cardoner Alvarez
    • Financial endowment: 117.370,00 €

Coronary arteriosclerotic disease is the leading cause of death in type 1 diabetes (DMI). It is often asymptomatic and appears as outgoing myocardial ischemia (IMS). This can be detected by stress myocardial perfusion imaging (PIPMes) tests and predicts future coronary events. According to the AHA / ADA, classic cardiovascular risk factors (CVs) underestimate that CV risk. The widespread use of PIPMes is unfeasible, so to better identify the patients most likely to have IMS is a PIPME (and treat them before the first coronary event) we propose to evaluate as potential biomarkers of IMS (isolated or together), in 100 patients with MI (> 10th evolution, without clinical CV disease):

  1. Glycemic variability (standard deviation-DE- from the continuous glucose monitoring records- MCG- (primary objective);
  2. Whole-pancreatic secretion following a TCM- (C-peptide, glucagon, GLP-1) mixed meal test;
  3. Number and size of lipoproteins (NMR spectroscopy);
  4. Markers of myocardial stress (NT-proBNP, hs-cTnT), inflammation (hs-CRP, IL-6, TNF-alpha 1 and 2 soluble receptors), endothelial dysfunction (ICAM, VCAM, E-selectin), and advanced glycosylation ( N-carboxy-methyl-lysine; accumulation in the skin)
  5. Plasma microRNAs;
  6. Retinal neuro-degeneration (NDR) (optical coherence tomography).

Methods: Patients will be evaluated for basic clinical features, IMS (with PIPME), and all potential biomarkers mentioned.

It is expected that IMS will be associated with more DE in the MCG, more atherogenic lipoprotein profile, specific profile of micro RNAs, lower C-peptic and GLP-1 concentrations and higher markers, and higher NDR.

The execution period of this project began on January 1, 2016 and will end on December 31, 2018, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI15 / 00567 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF).

    • IP: Dr. José Miguel González Clemente
    • Financial endowment: 134.915,00 €

El main goal of this project is to evaluate the longitudinal changes in biomarkers and inflammatory factors before and after a computerized cognitive rehabilitation intervention in patients with a psychotic disorder in the early stages of the disease to evaluate if baseline markers can predict the response or if the intervention is associated with an improvement in biochemical / hormonal parameters.

Methodology: Randomized, cross-over, single-blind clinical trial. 40 young patients (18-40) with a psychotic change of <3 years of evolution will be included. They will be randomized into 2 branches of treatment (cognitive rehabilitation vs. usual treatment. The cognitive rehabilitation intervention will be a computerized program of intensive cognitive rehabilitation (60 total hours, 4-5 hours / week, 3 months) using the Neuropersonal Trainer platform. Three months will cross both branches (the group that did the usual treatment will go through cognitive rehabilitation, and vice versa) All the patients will have a valuation 3 months after the completion of the cognitive rehabilitation The clinical evaluations (basal, 3 and 6 months in the subgroup of delayed onset) will include a cognitive battery (CANTAB for schizophrenia), Hinting Tasks, cognitive bias scale, PANSS, Calbary-Depression, PSP and stress measures (perceived stress, life events, childhood maltreatment) hormones (cortisol, prolactin) ) and inflammatory factors (c-reactive protein, fibrinogen) in serum and cortisol in saliva (respues cortisol upon awakening and area under the curve during clinical evaluations). A statistical analysis will be performed by intention to treat and by protocol.

The execution period of this project began on January 1, 2016 and will end on December 31, 2018, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI15 / 01386 project, integrated into the National R + D + I Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF).

    • IP: Dr. Javier Labad Arias
    • Financial endowment: 55.055,00 €

El overall objective of this coordinated project is to test the following hypotheses:

  1. The pulmonary microbiome in chronic obstructive pulmonary disease (COPD) is different in patients with frequent episodes of exacerbation (AF), compared to those who do not have it (NA).
  2. The microbial profile of the AF patient is associated with a differentiated local and systemic inflammatory and immune pattern.
  3. The inflammatory and immune characteristics of COPD are modulated by the gut microbiome.

The project is based on bronchoalveolar lavage (BAL) for the sampling of the pulmonary microbiome, and includes the analysis of regional (intrapulmonary) and temporal variability. The project will also evaluate the correlation between the BAL and the samples obtained from the proximal airway (oral cavity, oropharynx and sputum), and the representativeness of the pulmonary microbiome in them. A cohort of patients with COPD (n = 50 AF and n = 50 NA), and of healthy subjects (n = 30), matched by age, sex and tobacco consumption, will be created, from which the clinical stability samples will be obtained. previously required respiratory secretions, with repeated sampling in one quarter of the participants at 6 months.

The coordinating project will determine the bacterial and fungal flora by analysis of 16S rRNA and STI, and in a quarter of the participants the virus and the functional metagenome of the identified microbial flora. The coordinated subprojects will determine the regional variability of the pulmonary microbiome, the local and systemic inflammatory and immune response, and the relationship between the gut microbiome and the inflammatory and clinical features of the disease.

The project dataset will be analyzed with integrative methodologies based on network analysis, with the final aim of improving the understanding of the pathogenesis of COPD and its exacerbations, as a way to obtain new therapeutic alternatives.

The execution period of this project began on January 1, 2016 and will end on December 31, 2018, except for circumstances that are outside the institution need to request an extension.

This work is funded by the PI15 / 00167 project, integrated into the National R&D Plan and co-financed by the Carlos III Health Institute (ISCIII)-Directorate-General for Evaluation and the European Regional Development Fund (ERDF).

    • IP: Dr. Eduard Monsó Molas
    • Financial endowment: 159.115,00 €

The aim of the projects is, within a pre-commercial public procurement framework, to find solutions to empower patients through professional stress recovery and prevention services.

IP: Carme Colilles

Period: 01/01/2017 – 31/12/2020

Financing: Parc Taulí: € 541.350 (Consortium: € 4.191.300)

The aim is to create a web of good communication practices for people with severe disabilities who cannot use oral language, accessible for use in hospitals, schools and for individuals, in order to use communication with these people.

IP: Loreno Joga Elvira

Period: 01/10/2015 – 30/06/2018

Financing: Parc Taulí: € 25.465 (Consortium: € 117.920)

Telemonitoring and Telemedicine for Hospitals Assisted by ICT for Life saving co-morbid patients in Europe within a personalized care program of the EU

The goal is to develop an independent, interoperable platform for detecting the most at-risk patients in the ICU and improving critical care for patients through telemedicine.

IP: Lluís Blanch Torra

Period: 01/06/2016 – 31/05/2019

Financing: Parc Taulí: € 155.550 (Consortium: € 777.750)